Spyre Therapeutics (SYRE)
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
Spyre Therapeutics Announces Positive Interim Phase 1 Results for SPY003, Its Novel, Half-Life Extended anti-IL-23 Antibody
📈 **POSITIVE** • Medium confidence analysis (69%) • Strong positive clinical catalyst • Significant growth potential **Sentiment:** Positive (82%) **Content type:** Clinical